American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • 2017
  • »
  • March

FDA approves Noctivia for adults who deal with nocturnal polyuria

American Pharmacy News Reports | Mar 7, 2017
Noctivia nasal spray has gained FDA approval for adults who deal with nocturnal polyuria.

The U.S. Food and Drug Administration has approved Noctivia nasal spray for adults who deal with nocturnal polyuria, a condition that causes overproduction of urine during the night. Read More »

FDA approves ALK's application for dust mite allergy tablet

American Pharmacy News Reports | Mar 8, 2017
The medication is specially suited to address house dust mite-induced rhinitis.

The Food and Drug Administration has approved ALK's Biologics License Application for a sublingual immunotherapy tablet aimed at combating the negative effects caused by dust mite allergies.  Read More »

Study links PPIs to kidney failure in 125,000 patients

American Pharmacy News Reports | Mar 8, 2017
The study found that 125,000 individuals who used PPIs suffered from kidney failure.

In a recent February 2017 study, by Kidney International, found that Proton Pump Inhibitors (PPIs), may cause adverse effects on the human kidney.  Read More »

California pharmacists cleared to prescribe contraceptives in some cases

American Pharmacy News Reports | Mar 8, 2017
Pharmacists will suggest that the women return for a follow-up visit.

California Pharmacists are now legally permitted to prescribe oral, transdermal and vaginal forms of hormonal contraceptives in certain situations.  Read More »

Janssen releases Phase 3 study findings for psoriasis treatment

American Pharmacy News Reports | Mar 8, 2017
The majority of patients treated with guselkumab achieved high levels of skin improvement.

Janssen Research & Development LLC (Janssen) recently announced findings from two Phase 3 studies reporting the efficacy and safety of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Read More »

Arquette to head National Association of Specialty Pharmacy

American Pharmacy News Reports | Mar 8, 2017
Sheila Arquette has been involved in the specialty pharmacy industry for years.

The National Association of Specialty Pharmacy named Sheila Arquette its new executive director.  Read More »

Takeda, Cognition Kit to investigate depression diagnosis app

American Pharmacy News Reports | Mar 9, 2017
An Apple Watch app could assess cognitive function in patients with Major Depressive Disorder.

Takeda Pharmaceuticals U.S.A. Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd., is collaborating with Cognition Kit Ltd., a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Ltd., to pilot the use of an Apple Watch app that assesses cognitive function in patients with Major Depressive Disorder. Read More »

Sandoz presents highlights from Phase 3 study of Humira biosimilar

American Pharmacy News Reports | Mar 9, 2017
In  the study, 67 percent of patients saw a 75 percent improvement at Week 16 for the treatment of psoriasis.

Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »

Keck student earns $1,000 scholarship from MD Labs

American Pharmacy News Reports | Mar 9, 2017
The $1,000 scholarship is offered each year for graduate students who are pursuing a career in pharmacy.

Kim Nguyen, La Puenta, Calif., was recently named the recipient of the MD Labs/Rxight Scholarship Supporting Excellence in Pharmacy Students. Read More »

Janssen lifts voluntary hold on FAAH Phase 2 study

American Pharmacy News Reports | Mar 9, 2017
Janssen had not been given any indication of negative results from their Phase 2 studies with the FAAH inhibitor.

Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies.  Read More »

Epic to be implemented at CVS Specialty and Accordant

American Pharmacy News Reports | Mar 9, 2017
The Epic EHR system will be used by CVS Specialty.

CVS Health has selected Epic as its new electronic health record system for its more specialized care program, CVS Specialty, which includes Accordant, a care management program available to individuals suffering from rare diseases. Read More »

Goodlatte calls on legal profession to crack down on trial lawyer drug lawsuit ads

LocalLabs News Service | Mar 10, 2017
U.S. House Judiciary Chairman Bob Goodlatte (R-VA)

U.S. House Judiciary Chairman Bob Goodlatte (R-VA) has sent letters to the American Bar Association and every state bar association, urging the organizations to adopt requirements for warnings on trial lawyer advertisements that urge patients to discontinue the use of some medicines. Read More »

Amgen to release results of Repatha cardiovascular outcomes trial

American Pharmacy News Reports | Mar 10, 2017
The presentation will include two analyses that explore prescription rejection rates and access barriers for PCSK9 inhibitors.

Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »

FDA to review type 2 diabetes drugs from Merck and Pfizer

American Pharmacy News Reports | Mar 10, 2017
The NDAs are for medicines containing ertugliflozin, an investigational SGLT2 inhibitor.

Merck, which is known as MSD outside the United States and Canada, and Pfizer Inc. recently announced the acceptance for review of three New Drug Applications by the U.S. Food and Drug Administration. Read More »

Bristol-Myers and Pfizer to present on diverse topics at ACC

American Pharmacy News Reports | Mar 10, 2017
The companies will present real-world data analyses that showcase their commitment to understanding direct oral anticoagulants in clinical practice.

Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »

Ampion closer to approval to treat severe osteoarthritis of the knee

American Pharmacy News Reports | Mar 10, 2017
The study is to be completed prior to the submission of a Biologicals Licensing Application. 

The Office of Tissue Advancement Therapies, a branch of the Center for Biologics Evaluation and Research of the FDA, has progressed toward the acceptance of Ampio Pharmaceuticals' Ampion for a viable treatment option for severe osteoarthritis of the knee. Read More »

Biosimilars Council appeals to Supreme Court for lower drug prices

American Pharmacy News Reports | Mar 11, 2017
The Association for Accessible Medicines has appealed the ruling to the Supreme Court.

The Biosimilars Council is hoping the Supreme Court will acknowledge the savings that biosimilar medications can offer to both patients and health systems.  Read More »

Court upholds Pernix's Zohydro ER patent

American Pharmacy News Reports | Mar 14, 2017
Pernix has disputed a generic version of Zohydro ER generated by Actavis Laboratories.

Pernix Therapeutics Holdings Inc. recently announced that it has been given positive feedback on its litigation in regards to the proposed generic version of Zohydro ER with Actavis Laboratories FL Inc. Read More »

Pfizer gives additional $530,000 for UICC breast cancer research

American Pharmacy News Reports | Mar 15, 2017
Pfizer launched the challenge with UICC in 2015 with $760,000 in funding.

Pfizer Inc. is renewing its partnership with the Union for International Cancer Control through a grant of $530,000 for the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge. Read More »

Alabama legislators discuss collaborative drug therapy management

Mark Iandolo | Mar 15, 2017
Many Alabama pharmacists work with physicians to provide services related to CDTM.

The American Society of Health-System Pharmacists (ASHP) recently announced that the current Alabama legislature session is seeking to attempt to have the state codify collaborative drug therapy management (CDMT) as part of pharmacy practice. Read More »

  • «
  • 1
  • 2 (current)
  • 3
  • 4
  • 5
  • »
Trending

Dr. Allison Hill DC State Board of Pharmacy Chairperson

Modified services and closures announced for DC Emancipation Day observance

 Jeff Harrell Board President

Arkansas law bans PBMs from pharmacy ownership to curb anti-competitive practices

Shaun Noorian, Founder, CEO & Chairman, Empower Pharmacy

Empower Pharmacy ranks among fastest-growing private firms in Southwest

 Jeff Harrell Board President

NCPA reacts to Trump's drug pricing executive order targeting pharmacy benefit managers

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up